Novartis has jumped into the competition in the macular degeneration treatment market with ‘Beovu.’ Emphasizing its longer treatment interval, the new drug is fiercely chasing the market leader ‘Eylea.’

Beovu (brolucizumab) is a treatment for wet (neovascular) age-related macular degeneration (AMD) launched by Novartis as a successor to its ophthalmology drug ‘Lucentis.’ The prefilled syringe formulation of Beovu was approved in Korea last July and is being reimbursed from this month.

The biggest benefit of Beovu is its longer treatment interval. Beovu is administered once every 4 weeks for the first three doses, followed by once every 12 weeks. Bayer’s Eylea is also admin